Cytokinetics (CYTK) Change in Receivables (2016 - 2026)
Cytokinetics (CYTK) posted quarterly Change in Receivables of -$10.9 million for Q1 2026, up 25.28% year-over-year from -$8.7 million in Q1 2025, and down 168.54% quarter-over-quarter from $16.0 million in Q4 2025.
Powered by 
Analysis
Cytokinetics (CYTK) Change in Receivables (2016 - 2026) Analysis & Trends
Cytokinetics (CYTK) has reported Change in Receivables for 11 consecutive years, with -$10.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Receivables rose 25.28% year-over-year to -$10.9 million; the TTM figure through Mar 2026 stood at $4.8 million (up 308.74% YoY), while the FY2025 annual figure was $1.1 million, down 92.75% from the prior year.
- Change in Receivables declined to -$10.9 million in Q1 2026 per CYTK's latest filing, from $16.0 million in the prior quarter.
- Across five years, Change in Receivables topped out at $16.4 million in Q4 2024 and bottomed at -$50.8 million in Q1 2022.
- Historically, Change in Receivables has averaged -$2.9 million across 5 years, with a median of -$449000.0 in 2024.
- Annual changes were most pronounced in 2022 — Change in Receivables plunged 54103.19% — and 2024, when it jumped 1449.18%.
- Cytokinetics' Change in Receivables stood at -$2.1 million in 2022, then soared by 43.36% to -$1.2 million in 2023, then surged by 1449.18% to $16.4 million in 2024, then dropped by 2.74% to $16.0 million in 2025, then slumped by 168.54% to -$10.9 million in 2026.
- Business Quant data shows CYTK's Change in Receivables at -$10.9 million in Q1 2026, $16.0 million in Q4 2025, and -$6.6 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -53.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 117.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 31.60 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Cytokinetics | 9.63 Bn | 8.46 Bn | 25.89 Mn | 17.61 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 17.61 Mn |
| Mar 31, 2026 | -10.94 Mn |
| Dec 31, 2025 | 15.96 Mn |
| Sep 30, 2025 | -6.60 Mn |
| Jun 30, 2025 | 6.40 Mn |
| Mar 31, 2025 | -14.64 Mn |
| Dec 31, 2024 | 16.41 Mn |
| Sep 30, 2024 | 244,000.00 |
| Jun 30, 2024 | -834,000.00 |
| Mar 31, 2024 | -449,000.00 |
| Dec 31, 2023 | -1.22 Mn |
| Sep 30, 2023 | 1.51 Mn |
| Jun 30, 2023 | -21,000.00 |
| Mar 31, 2023 | 859,000.00 |
| Dec 31, 2022 | -2.15 Mn |
| Sep 30, 2022 | 321,000.00 |
| Jun 30, 2022 | -4.08 Mn |
| Mar 31, 2022 | -50.76 Mn |
| Dec 31, 2021 | 51.18 Mn |
| Sep 30, 2021 | -2.06 Mn |